Risk appeared to be greater in trials testing >1 g/day dosing
WEDNESDAY, Oct. 13, 2021 (HealthDay News) — Long-term marine omega-3 supplementation is associated with an increased risk for atrial fibrillation (AF), according to a study published online Oct. 6 in Circulation.
Baris Gencer, M.D., M.P.H., from Geneva University Hospitals in Switzerland, and colleagues conducted a systematic literature review to identify randomized controlled trials assessing the effects of marine omega-3 fatty acids supplementation on cardiovascular outcomes. The meta-analysis included seven trials (81,210 patients).
The researchers reported that nearly three-quarters of participants (72.6 percent) were enrolled in trials testing ≤1 g/day and 27.4 percent in trials testing >1 g/day of omega-3 fatty acids. The mean age of participants was 65 years, with 39 percent women and an average follow-up of 4.9 years. The meta-analysis showed the use of marine omega-3 fatty acid supplements was associated with an increased risk for AF (2,905; hazard ratio [HR], 1.25), with the risk higher in the trials testing >1 g/day (HR, 1.49) versus those testing ≤1 g/day (HR, 1.12).
“Since the benefit of omega-3 fatty acids also appears to be dose dependent, the associated risk of AF should be balanced against the benefit on atherosclerotic cardiovascular outcomes,” the authors write.
Abstract/Full Text (subscription or payment may be required)
Retinal Imaging Can ID Atrial Fibrillation Years Before Diagnosis 
2009 to 2023 Saw Surge in Probiotic Supplement Use 
NOACs Linked to Slower Cognitive Decline in Patients With A-Fib, Alzheimer Disease 
Central Adiposity Reclassifies Cardiovascular Risk Across BMI Spectrum 
Elevated C-Reactive Protein Linked to Increased Risk for Incident Heart Failure, All-Cause Mortality 
UACR, UPCR Provide Indistinguishable Prognostic Information in CKD 
Use of SAMA, SABA Linked to Cardiovascular Events, Mortality in Asthma, COPD 
Smartwatches Significantly Overestimate How Many Calories Are Burned 
